Amphastar Pharmaceuticals, Inc. (AMPH) 10-Year Financial Performance & Capital Metrics

AMPH • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsComplex Generics

AboutAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Show more

Revenue $732M +13.6%
EBITDA $263M +10.0%
Net Income $160M +16.0%
EPS (Diluted) 3.06 +17.7%
Gross Margin 51.08% -6.3%
EBITDA Margin 35.88% -3.2%
Operating Margin 28.06% -8.2%
Net Margin 21.79% +2.1%
ROE 23.26% -1.2%
ROIC 13.11% -29.3%
Debt/Equity 0.89 -8.9%
Interest Coverage 6.77 -6.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 21.9%
✓Strong 5Y profit CAGR of 26.7%
✓FCF machine: 23.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.8%
✓Healthy 5Y average net margin of 15.2%

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.27%

5Y17.82%

3Y18.69%

TTM0.3%

Profit (Net Income) CAGR

10Y-

5Y26.66%

3Y36.94%

TTM-29.22%

EPS CAGR

10Y-

5Y25.57%

3Y34.77%

TTM-24.67%

ROCE

10Y Avg6.83%

5Y Avg13.67%

3Y Avg17.78%

Latest15.27%

Peer Comparison

Complex Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AMPHAmphastar Pharmaceuticals, Inc.	1.19B	26.00	8.50	13.59%	15.43%	14.37%	14.43%	0.89
AMRXAmneal Pharmaceuticals, Inc.	4.15B	13.19	-34.71	16.73%	0.2%	-13.94%	5.31%
ANIPANI Pharmaceuticals, Inc.	1.92B	85.29	-82.01	26.2%	4.61%	7.53%	2.46%	1.46

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	251.52M	255.16M	240.18M	294.67M	322.36M	349.85M	437.77M	498.99M	644.39M	731.97M
Revenue Growth %	0.2%	0.01%	-0.06%	0.23%	0.09%	0.09%	0.25%	0.14%	0.29%	0.14%
Cost of Goods Sold+	174.17M	150.98M	149.38M	187.68M	190.43M	206.51M	238.03M	250.13M	293.27M	358.11M
COGS % of Revenue	0.69%	0.59%	0.62%	0.64%	0.59%	0.59%	0.54%	0.5%	0.46%	0.49%
Gross Profit+	77.35M	104.19M	90.8M	106.98M	131.92M	143.34M	199.74M	248.86M	351.12M	373.86M
Gross Margin %	0.31%	0.41%	0.38%	0.36%	0.41%	0.41%	0.46%	0.5%	0.54%	0.51%
Gross Profit Growth %	0.51%	0.35%	-0.13%	0.18%	0.23%	0.09%	0.39%	0.25%	0.41%	0.06%
Operating Expenses+	84.04M	88.5M	94.33M	115.61M	131.96M	132.39M	129.85M	141.36M	154.13M	168.44M
OpEx % of Revenue	0.33%	0.35%	0.39%	0.39%	0.41%	0.38%	0.3%	0.28%	0.24%	0.23%
Selling, General & Admin	46.97M	47.3M	50.92M	58.04M	63.11M	65.16M	68.92M	66.59M	80.39M	94.52M
SG&A % of Revenue	0.19%	0.19%	0.21%	0.2%	0.2%	0.19%	0.16%	0.13%	0.12%	0.13%
Research & Development	37.06M	41.2M	43.41M	57.56M	68.85M	67.23M	60.93M	74.77M	73.74M	73.91M
R&D % of Revenue	0.15%	0.16%	0.18%	0.2%	0.21%	0.19%	0.14%	0.15%	0.11%	0.1%
Other Operating Expenses	0	-746K	0	0	0	0	0	0	0	0
Operating Income+	-6.9M	15.69M	-895K	-8.62M	-39K	10.95M	69.89M	107.5M	196.99M	205.42M
Operating Margin %	-0.03%	0.06%	-0%	-0.03%	-0%	0.03%	0.16%	0.22%	0.31%	0.28%
Operating Income Growth %	0.62%	3.27%	-1.06%	-8.63%	1%	281.87%	5.38%	0.54%	0.83%	0.04%
EBITDA+	6.35M	30.26M	14.91M	7.89M	21.08M	36.13M	96.42M	135.77M	238.76M	262.62M
EBITDA Margin %	0.03%	0.12%	0.06%	0.03%	0.07%	0.1%	0.22%	0.27%	0.37%	0.36%
EBITDA Growth %	2.8%	3.76%	-0.51%	-0.47%	1.67%	0.71%	1.67%	0.41%	0.76%	0.1%
D&A (Non-Cash Add-back)	13.25M	14.56M	15.81M	16.52M	21.12M	25.18M	26.53M	28.27M	41.78M	57.2M
EBIT	-9.38M	15.97M	2.08M	-9.68M	60.35M	5.01M	85.02M	117.89M	198.52M	220.11M
Net Interest Income+	-672K	-754K	-401K	213K	878K	268K	-284K	-525K	-21.7M	-19.73M
Interest Income	315K	270K	425K	456K	997K	642K	601K	1.32M	5.46M	10.61M
Interest Expense	987K	1.02M	826K	243K	119K	374K	885K	1.85M	27.16M	30.34M
Other Income/Expense	-3.47M	-746K	2.52M	-1.3M	60.27M	-6.32M	14.04M	7.37M	-27.61M	-16.23M
Pretax Income+	-10.36M	14.95M	1.62M	-9.93M	60.23M	4.64M	83.93M	114.86M	169.38M	189.19M
Pretax Margin %	-0.04%	0.06%	0.01%	-0.03%	0.19%	0.01%	0.19%	0.23%	0.26%	0.26%
Income Tax+	-7.58M	4.41M	-2.88M	-3.27M	13.72M	3.54M	20.63M	23.48M	31.83M	29.67M
Effective Tax Rate %	0.27%	0.7%	2.78%	0.58%	0.81%	0.3%	0.74%	0.8%	0.81%	0.84%
Net Income+	-2.79M	10.53M	4.51M	-5.74M	48.94M	1.4M	62.12M	91.39M	137.54M	159.52M
Net Margin %	-0.01%	0.04%	0.02%	-0.02%	0.15%	0%	0.14%	0.18%	0.21%	0.22%
Net Income Growth %	0.74%	4.78%	-0.57%	-2.27%	9.53%	-0.97%	43.27%	0.47%	0.51%	0.16%
Net Income (Continuing)	-2.79M	9.82M	3.65M	-6.66M	46.51M	1.1M	63.3M	91.39M	137.54M	159.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	31.92M	46.16M	46.42M	0	0	0	0
EPS (Diluted)+	-0.06	0.22	0.09	-0.12	0.98	0.03	1.25	1.74	2.60	3.06
EPS Growth %	0.75%	4.55%	-0.59%	-2.33%	9.17%	-0.97%	42.71%	0.39%	0.49%	0.18%
EPS (Basic)	-0.06	0.23	0.10	-0.12	1.04	0.03	1.30	1.88	2.85	3.29
Diluted Shares Outstanding	44.96M	47.5M	48.37M	46.4M	49.91M	49.12M	49.78M	52.43M	53M	52.06M
Basic Shares Outstanding	44.96M	45.38M	46.11M	46.4M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	175.93M	184.1M	187.78M	220.34M	255.24M	279.68M	318.12M	378.32M	489.6M	534.07M
Cash & Short-Term Investments	66.07M	72.88M	68.23M	89.17M	89.52M	105.62M	136.67M	175.76M	256.81M	221.65M
Cash Only	66.07M	72.35M	65.59M	86.34M	75.55M	92.64M	126.35M	156.1M	144.3M	151.61M
Short-Term Investments	0	527K	2.63M	2.83M	13.96M	12.98M	10.32M	19.66M	112.51M	70.04M
Accounts Receivable	33.23M	26.78M	36M	52.16M	45.38M	66M	78.8M	88.8M	115.47M	138.04M
Days Sales Outstanding	48.23	38.3	54.7	64.61	51.38	68.86	65.7	64.96	65.4	68.83
Inventory	70.67M	79.75M	63.61M	69.32M	110.5M	96.83M	92.81M	103.58M	105.83M	153.74M
Days Inventory Outstanding	148.09	192.81	155.42	134.82	211.79	171.15	142.31	151.16	131.72	156.7
Other Current Assets	1.52M	1.41M	10.19M	4.2M	9.85M	4.45M	2.56M	2.61M	11.49M	20.65M
Total Non-Current Assets+	214.2M	243.64M	266.89M	293.22M	331.73M	351.55M	353.41M	363.67M	1.02B	1.04B
Property, Plant & Equipment	142.16M	152.94M	185.34M	210.42M	253.55M	280.71M	271.49M	264.57M	315.64M	344.63M
Fixed Asset Turnover	1.77x	1.67x	1.30x	1.40x	1.27x	1.25x	1.61x	1.89x	2.04x	2.12x
Goodwill	3.73M	3.98M	4.46M	3.95M	3.63M	3.94M	3.31M	3.13M	3.22M	3.05M
Intangible Assets	36.17M	46.33M	40.68M	38.32M	37.52M	36.67M	35.56M	34.17M	610.08M	587.61M
Long-Term Investments	0	0	0	0	0	0	3.98M	2.41M	15.21M	11M
Other Non-Current Assets	4.7M	9.39M	8.66M	9.92M	11.16M	5.25M	16.66M	20.86M	25.91M	25.99M
Total Assets+	390.14M	427.74M	454.67M	513.56M	586.97M	631.24M	671.53M	741.99M	1.51B	1.58B
Asset Turnover	0.64x	0.60x	0.53x	0.57x	0.55x	0.55x	0.65x	0.67x	0.43x	0.46x
Asset Growth %	0%	0.1%	0.06%	0.13%	0.14%	0.08%	0.06%	0.1%	1.04%	0.04%
Total Current Liabilities+	59.95M	60.62M	67.19M	106.83M	90.01M	112.2M	103.81M	94.86M	225.41M	173.76M
Accounts Payable	13.87M	19.93M	16.63M	31.32M	25.06M	24.36M	22.21M	20.5M	25.44M	30.51M
Days Payables Outstanding	29.07	48.19	40.63	60.92	48.03	43.05	34.06	29.92	31.66	31.1
Short-Term Debt	10.93M	5.37M	6.31M	18.23M	10.92M	12.26M	2.2M	3.05M	436K	234K
Deferred Revenue (Current)	643K	97K	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	0	7.71M	7.78M	0	30.12M	25.19M	23.16M	17.55M	0	0
Current Ratio	2.93x	3.04x	2.79x	2.06x	2.84x	2.49x	3.06x	3.99x	2.17x	3.07x
Quick Ratio	1.76x	1.72x	1.85x	1.41x	1.61x	1.63x	2.17x	2.90x	1.70x	2.19x
Cash Conversion Cycle	167.24	182.93	169.5	138.51	215.14	196.96	173.95	186.2	165.46	194.43
Total Non-Current Liabilities+	34.67M	37.87M	50.14M	42.37M	69.43M	70.31M	122.2M	118.47M	648.08M	671.41M
Long-Term Debt	30.16M	32.36M	40.84M	31.98M	38.89M	33.91M	74.38M	72.84M	589.58M	601.63M
Capital Lease Obligations	0	0	0	0	16.82M	17.74M	25.1M	23.69M	29.72M	41.88M
Deferred Tax Liabilities	497K	2.3M	2.24M	1.45M	867K	5.45M	7.07M	7.37M	6.07M	6.96M
Other Non-Current Liabilities	3.17M	3.96M	7.94M	9.36M	12.86M	13.21M	15.65M	14.56M	22.72M	20.95M
Total Liabilities	94.63M	98.48M	117.34M	149.2M	159.44M	182.51M	226.01M	213.33M	873.49M	845.17M
Total Debt+	41.1M	37.72M	47.16M	50.21M	66.63M	67.27M	104.66M	102.58M	623.64M	650.55M
Net Debt	-24.98M	-34.63M	-18.44M	-36.12M	-8.93M	-25.37M	-21.69M	-53.52M	479.35M	498.94M
Debt / Equity	0.14x	0.11x	0.14x	0.14x	0.16x	0.15x	0.23x	0.19x	0.98x	0.89x
Debt / EBITDA	6.47x	1.25x	3.16x	6.36x	3.16x	1.86x	1.09x	0.76x	2.61x	2.48x
Net Debt / EBITDA	-3.93x	-1.14x	-1.24x	-4.58x	-0.42x	-0.70x	-0.22x	-0.39x	2.01x	1.90x
Interest Coverage	-6.99x	15.32x	-1.08x	-35.49x	-0.33x	29.29x	78.97x	58.23x	7.25x	6.77x
Total Equity+	295.51M	329.25M	337.33M	364.36M	427.53M	448.72M	445.52M	528.66M	639.42M	732.3M
Equity Growth %	0.05%	0.11%	0.02%	0.08%	0.17%	0.05%	-0.01%	0.19%	0.21%	0.15%
Book Value per Share	6.57	6.93	6.97	7.85	8.57	9.13	8.95	10.08	12.06	14.07
Total Shareholders' Equity	295.51M	329.25M	337.33M	332.44M	381.37M	402.31M	445.52M	528.66M	639.42M	732.3M
Common Stock	5K	5K	5K	5K	5K	5K	6K	6K	6K	6K
Retained Earnings	60.32M	70.86M	76.23M	67.48M	116.37M	117.77M	180.34M	271.72M	409.27M	568.79M
Treasury Stock	-10.17M	-20.03M	-50.7M	-75.48M	-97.63M	-121.81M	-150.48M	-189.52M	-247.43M	-332.71M
Accumulated OCI	-2.48M	-4.7M	-2.1M	-4.01M	-4.69M	-3.72M	-6.76M	-8.62M	-8.48M	-9.18M
Minority Interest	0	0	0	31.92M	46.16M	46.42M	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	10.68M	38.56M	39.21M	38.19M	41.76M	57.27M	97.99M	89.18M	183.5M	213.39M
Operating CF Margin %	0.04%	0.15%	0.16%	0.13%	0.13%	0.16%	0.22%	0.18%	0.28%	0.29%
Operating CF Growth %	-0.49%	2.61%	0.02%	-0.03%	0.09%	0.37%	0.71%	-0.09%	1.06%	0.16%
Net Income	-2.79M	10.53M	4.51M	-6.66M	46.51M	1.1M	63.3M	91.39M	137.54M	159.52M
Depreciation & Amortization	13.25M	14.56M	15.44M	16.52M	21.12M	25.18M	26.75M	28.74M	41.78M	57.2M
Stock-Based Compensation	12.81M	15.12M	17.09M	16.68M	17.3M	20.5M	18.69M	17.86M	20.24M	24.37M
Deferred Taxes	-7.88M	-3.27M	3.93M	-1.88M	7.55M	1.12M	4.21M	-15.75M	-13.74M	-17.87M
Other Non-Cash Items	420K	1.31M	-2.34M	1.43M	1.04M	240K	-13.03M	-878K	21.89M	4.71M
Working Capital Changes	-5.14M	297K	582K	12.1M	-51.75M	9.13M	-1.92M	-32.18M	-24.21M	-14.55M
Change in Receivables	-11.01M	6.38M	-8.1M	-16.3M	6.7M	-20.16M	-14.92M	-10.13M	-26.09M	-21.67M
Change in Inventory	9.78M	-9.71M	18.65M	-5.98M	-41.1M	15.3M	1.26M	-11.75M	-1.72M	-48.8M
Change in Payables	-3.13M	-823K	6.69M	29.16M	-17.94M	14.96M	3.02M	-736K	13.24M	63.56M
Cash from Investing+	-16.93M	-39.5M	-38.76M	-42.18M	-50.53M	-36.41M	-28.67M	-32.78M	-649.12M	-124.93M
Capital Expenditures	-16.05M	-21.38M	-35.1M	-46.81M	-41.55M	-33.85M	-27.46M	-24.03M	-38.17M	-41.04M
CapEx % of Revenue	0.06%	0.08%	0.15%	0.16%	0.13%	0.1%	0.06%	0.05%	0.06%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-878K	-5.13M	-3.66M	198K	-157K	-1.41M	-2.61M	-1.37M	1.39M	-4.12M
Cash from Financing+	2.24M	7.14M	-7.72M	25.01M	-3.78M	-2.25M	-37.02M	-26.44M	454.09M	-80.95M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14.31M	21.5M	13.76M	8.95M	3.42M	23.06M	-40.24M	15.25M	-14.11M	-5.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.37M	17.18M	4.11M	-8.62M	207K	23.41M	70.54M	65.15M	145.34M	172.34M
FCF Margin %	-0.02%	0.07%	0.02%	-0.03%	0%	0.07%	0.16%	0.13%	0.23%	0.24%
FCF Growth %	-10.7%	4.2%	-0.76%	-3.1%	1.02%	112.1%	2.01%	-0.08%	1.23%	0.19%
FCF per Share	-0.12	0.36	0.08	-0.19	0.00	0.48	1.42	1.24	2.74	3.31
FCF Conversion (FCF/Net Income)	-3.83x	3.66x	8.70x	-6.66x	0.85x	40.82x	1.58x	0.98x	1.33x	1.34x
Interest Paid	1.94M	1.72M	1.88M	2.38M	2.44M	2.2M	2.11M	3.02M	17.57M	26.81M
Taxes Paid	146K	3.4M	4.88M	339K	5.72M	3.41M	8.1M	44.44M	49M	40.1M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.97%	3.37%	1.35%	-1.64%	12.36%	0.32%	13.89%	18.76%	23.55%	23.26%
Return on Invested Capital (ROIC)	-1.96%	4.16%	-0.22%	-2%	-0.01%	1.95%	12.37%	17.94%	18.54%	13.11%
Gross Margin	30.75%	40.83%	37.8%	36.31%	40.92%	40.97%	45.63%	49.87%	54.49%	51.08%
Net Margin	-1.11%	4.13%	1.88%	-1.95%	15.18%	0.4%	14.19%	18.31%	21.34%	21.79%
Debt / Equity	0.14x	0.11x	0.14x	0.14x	0.16x	0.15x	0.23x	0.19x	0.98x	0.89x
Interest Coverage	-6.99x	15.32x	-1.08x	-35.49x	-0.33x	29.29x	78.97x	58.23x	7.25x	6.77x
FCF Conversion	-3.83x	3.66x	8.70x	-6.66x	0.85x	40.82x	1.58x	0.98x	1.33x	1.34x
Revenue Growth	19.51%	1.45%	-5.87%	22.69%	9.4%	8.53%	25.13%	13.98%	29.14%	13.59%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	-	712.81M
Product Growth	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	19.15M
Other Growth	-	-	-	-	-	-	-	-	-	-
Product revenues, net	-	-	-	-	-	-	-	-	593.24M	-
Product revenues, net Growth	-	-	-	-	-	-	-	-	-	-
Other revenues	-	-	-	-	-	-	-	-	51.16M	-
Other revenues Growth	-	-	-	-	-	-	-	-	-	-
Research and development services	-	-	-	-	-	-	-	4.3M	-	-
Research and development services Growth	-	-	-	-	-	-	-	-	-	-
Finished Pharmaceutical Products	-	-	-	-	-	-	419.57M	-	-	-
Finished Pharmaceutical Products Growth	-	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	14.94M	10.04M	23.61M	20.36M	18.48M	18.2M	-	-	-
Active Pharmaceutical Ingredient Growth	-	-	-32.84%	135.22%	-13.77%	-9.23%	-1.52%	-	-	-
Epinephrine	-	-	17.8M	-	-	-	-	-	-	-
Epinephrine Growth	-	-	-	-	-	-	-	-	-	-
Recombinant Human Insulin	20.8M	-	-	-	-	-	-	-	-	-
Recombinant Human Insulin Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	419.87M	486.83M	635.19M	707.68M
UNITED STATES Growth	-	-	-	-	-	-	-	15.95%	30.47%	11.41%
FRANCE	-	-	-	-	-	-	11.88M	7.46M	4.7M	19.95M
FRANCE Growth	-	-	-	-	-	-	-	-37.23%	-37.00%	324.58%
CHINA	-	-	-	-	-	-	6.02M	4.7M	4.5M	4.34M
CHINA Growth	-	-	-	-	-	-	-	-21.98%	-4.09%	-3.68%
U	243.29M	249.01M	234.32M	279.12M	304.9M	333.09M	-	-	-	-
U Growth	-	2.35%	-5.90%	19.12%	9.23%	9.25%	-	-	-	-
C	-	-	-	-	1.48M	3.16M	-	-	-	-
C Growth	-	-	-	-	-	113.44%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Amphastar Pharmaceuticals, Inc. (AMPH) has a price-to-earnings (P/E) ratio of 8.5x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Amphastar Pharmaceuticals, Inc. (AMPH) reported $723.3M in revenue for fiscal year 2024. This represents a 254% increase from $204.3M in 2012.

Amphastar Pharmaceuticals, Inc. (AMPH) grew revenue by 13.6% over the past year. This is steady growth.

Yes, Amphastar Pharmaceuticals, Inc. (AMPH) is profitable, generating $111.6M in net income for fiscal year 2024 (21.8% net margin).

Dividend & Returns

Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity (ROE) of 23.3%. This is excellent, indicating efficient use of shareholder capital.

Amphastar Pharmaceuticals, Inc. (AMPH) generated $113.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Amphastar Pharmaceuticals, Inc. (AMPH) 10-Year Financial Performance & Capital Metrics

AMPH • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsComplex Generics

Revenue $732M +13.6%
EBITDA $263M +10.0%
Net Income $160M +16.0%
EPS (Diluted) 3.06 +17.7%
Gross Margin 51.08% -6.3%
EBITDA Margin 35.88% -3.2%
Operating Margin 28.06% -8.2%
Net Margin 21.79% +2.1%
ROE 23.26% -1.2%
ROIC 13.11% -29.3%
Debt/Equity 0.89 -8.9%
Interest Coverage 6.77 -6.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 21.9%
✓Strong 5Y profit CAGR of 26.7%
✓FCF machine: 23.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.8%
✓Healthy 5Y average net margin of 15.2%

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.27%

5Y17.82%

3Y18.69%

TTM0.3%

Profit (Net Income) CAGR

10Y-

5Y26.66%

3Y36.94%

TTM-29.22%

EPS CAGR

10Y-

5Y25.57%

3Y34.77%

TTM-24.67%

ROCE

10Y Avg6.83%

5Y Avg13.67%

3Y Avg17.78%

Latest15.27%

Peer Comparison

Complex Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AMPHAmphastar Pharmaceuticals, Inc.	1.19B	26.00	8.50	13.59%	15.43%	14.37%	14.43%	0.89
AMRXAmneal Pharmaceuticals, Inc.	4.15B	13.19	-34.71	16.73%	0.2%	-13.94%	5.31%
ANIPANI Pharmaceuticals, Inc.	1.92B	85.29	-82.01	26.2%	4.61%	7.53%	2.46%	1.46

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	251.52M	255.16M	240.18M	294.67M	322.36M	349.85M	437.77M	498.99M	644.39M	731.97M
Revenue Growth %	0.2%	0.01%	-0.06%	0.23%	0.09%	0.09%	0.25%	0.14%	0.29%	0.14%
Cost of Goods Sold+	174.17M	150.98M	149.38M	187.68M	190.43M	206.51M	238.03M	250.13M	293.27M	358.11M
COGS % of Revenue	0.69%	0.59%	0.62%	0.64%	0.59%	0.59%	0.54%	0.5%	0.46%	0.49%
Gross Profit+	77.35M	104.19M	90.8M	106.98M	131.92M	143.34M	199.74M	248.86M	351.12M	373.86M
Gross Margin %	0.31%	0.41%	0.38%	0.36%	0.41%	0.41%	0.46%	0.5%	0.54%	0.51%
Gross Profit Growth %	0.51%	0.35%	-0.13%	0.18%	0.23%	0.09%	0.39%	0.25%	0.41%	0.06%
Operating Expenses+	84.04M	88.5M	94.33M	115.61M	131.96M	132.39M	129.85M	141.36M	154.13M	168.44M
OpEx % of Revenue	0.33%	0.35%	0.39%	0.39%	0.41%	0.38%	0.3%	0.28%	0.24%	0.23%
Selling, General & Admin	46.97M	47.3M	50.92M	58.04M	63.11M	65.16M	68.92M	66.59M	80.39M	94.52M
SG&A % of Revenue	0.19%	0.19%	0.21%	0.2%	0.2%	0.19%	0.16%	0.13%	0.12%	0.13%
Research & Development	37.06M	41.2M	43.41M	57.56M	68.85M	67.23M	60.93M	74.77M	73.74M	73.91M
R&D % of Revenue	0.15%	0.16%	0.18%	0.2%	0.21%	0.19%	0.14%	0.15%	0.11%	0.1%
Other Operating Expenses	0	-746K	0	0	0	0	0	0	0	0
Operating Income+	-6.9M	15.69M	-895K	-8.62M	-39K	10.95M	69.89M	107.5M	196.99M	205.42M
Operating Margin %	-0.03%	0.06%	-0%	-0.03%	-0%	0.03%	0.16%	0.22%	0.31%	0.28%
Operating Income Growth %	0.62%	3.27%	-1.06%	-8.63%	1%	281.87%	5.38%	0.54%	0.83%	0.04%
EBITDA+	6.35M	30.26M	14.91M	7.89M	21.08M	36.13M	96.42M	135.77M	238.76M	262.62M
EBITDA Margin %	0.03%	0.12%	0.06%	0.03%	0.07%	0.1%	0.22%	0.27%	0.37%	0.36%
EBITDA Growth %	2.8%	3.76%	-0.51%	-0.47%	1.67%	0.71%	1.67%	0.41%	0.76%	0.1%
D&A (Non-Cash Add-back)	13.25M	14.56M	15.81M	16.52M	21.12M	25.18M	26.53M	28.27M	41.78M	57.2M
EBIT	-9.38M	15.97M	2.08M	-9.68M	60.35M	5.01M	85.02M	117.89M	198.52M	220.11M
Net Interest Income+	-672K	-754K	-401K	213K	878K	268K	-284K	-525K	-21.7M	-19.73M
Interest Income	315K	270K	425K	456K	997K	642K	601K	1.32M	5.46M	10.61M
Interest Expense	987K	1.02M	826K	243K	119K	374K	885K	1.85M	27.16M	30.34M
Other Income/Expense	-3.47M	-746K	2.52M	-1.3M	60.27M	-6.32M	14.04M	7.37M	-27.61M	-16.23M
Pretax Income+	-10.36M	14.95M	1.62M	-9.93M	60.23M	4.64M	83.93M	114.86M	169.38M	189.19M
Pretax Margin %	-0.04%	0.06%	0.01%	-0.03%	0.19%	0.01%	0.19%	0.23%	0.26%	0.26%
Income Tax+	-7.58M	4.41M	-2.88M	-3.27M	13.72M	3.54M	20.63M	23.48M	31.83M	29.67M
Effective Tax Rate %	0.27%	0.7%	2.78%	0.58%	0.81%	0.3%	0.74%	0.8%	0.81%	0.84%
Net Income+	-2.79M	10.53M	4.51M	-5.74M	48.94M	1.4M	62.12M	91.39M	137.54M	159.52M
Net Margin %	-0.01%	0.04%	0.02%	-0.02%	0.15%	0%	0.14%	0.18%	0.21%	0.22%
Net Income Growth %	0.74%	4.78%	-0.57%	-2.27%	9.53%	-0.97%	43.27%	0.47%	0.51%	0.16%
Net Income (Continuing)	-2.79M	9.82M	3.65M	-6.66M	46.51M	1.1M	63.3M	91.39M	137.54M	159.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	31.92M	46.16M	46.42M	0	0	0	0
EPS (Diluted)+	-0.06	0.22	0.09	-0.12	0.98	0.03	1.25	1.74	2.60	3.06
EPS Growth %	0.75%	4.55%	-0.59%	-2.33%	9.17%	-0.97%	42.71%	0.39%	0.49%	0.18%
EPS (Basic)	-0.06	0.23	0.10	-0.12	1.04	0.03	1.30	1.88	2.85	3.29
Diluted Shares Outstanding	44.96M	47.5M	48.37M	46.4M	49.91M	49.12M	49.78M	52.43M	53M	52.06M
Basic Shares Outstanding	44.96M	45.38M	46.11M	46.4M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	175.93M	184.1M	187.78M	220.34M	255.24M	279.68M	318.12M	378.32M	489.6M	534.07M
Cash & Short-Term Investments	66.07M	72.88M	68.23M	89.17M	89.52M	105.62M	136.67M	175.76M	256.81M	221.65M
Cash Only	66.07M	72.35M	65.59M	86.34M	75.55M	92.64M	126.35M	156.1M	144.3M	151.61M
Short-Term Investments	0	527K	2.63M	2.83M	13.96M	12.98M	10.32M	19.66M	112.51M	70.04M
Accounts Receivable	33.23M	26.78M	36M	52.16M	45.38M	66M	78.8M	88.8M	115.47M	138.04M
Days Sales Outstanding	48.23	38.3	54.7	64.61	51.38	68.86	65.7	64.96	65.4	68.83
Inventory	70.67M	79.75M	63.61M	69.32M	110.5M	96.83M	92.81M	103.58M	105.83M	153.74M
Days Inventory Outstanding	148.09	192.81	155.42	134.82	211.79	171.15	142.31	151.16	131.72	156.7
Other Current Assets	1.52M	1.41M	10.19M	4.2M	9.85M	4.45M	2.56M	2.61M	11.49M	20.65M
Total Non-Current Assets+	214.2M	243.64M	266.89M	293.22M	331.73M	351.55M	353.41M	363.67M	1.02B	1.04B
Property, Plant & Equipment	142.16M	152.94M	185.34M	210.42M	253.55M	280.71M	271.49M	264.57M	315.64M	344.63M
Fixed Asset Turnover	1.77x	1.67x	1.30x	1.40x	1.27x	1.25x	1.61x	1.89x	2.04x	2.12x
Goodwill	3.73M	3.98M	4.46M	3.95M	3.63M	3.94M	3.31M	3.13M	3.22M	3.05M
Intangible Assets	36.17M	46.33M	40.68M	38.32M	37.52M	36.67M	35.56M	34.17M	610.08M	587.61M
Long-Term Investments	0	0	0	0	0	0	3.98M	2.41M	15.21M	11M
Other Non-Current Assets	4.7M	9.39M	8.66M	9.92M	11.16M	5.25M	16.66M	20.86M	25.91M	25.99M
Total Assets+	390.14M	427.74M	454.67M	513.56M	586.97M	631.24M	671.53M	741.99M	1.51B	1.58B
Asset Turnover	0.64x	0.60x	0.53x	0.57x	0.55x	0.55x	0.65x	0.67x	0.43x	0.46x
Asset Growth %	0%	0.1%	0.06%	0.13%	0.14%	0.08%	0.06%	0.1%	1.04%	0.04%
Total Current Liabilities+	59.95M	60.62M	67.19M	106.83M	90.01M	112.2M	103.81M	94.86M	225.41M	173.76M
Accounts Payable	13.87M	19.93M	16.63M	31.32M	25.06M	24.36M	22.21M	20.5M	25.44M	30.51M
Days Payables Outstanding	29.07	48.19	40.63	60.92	48.03	43.05	34.06	29.92	31.66	31.1
Short-Term Debt	10.93M	5.37M	6.31M	18.23M	10.92M	12.26M	2.2M	3.05M	436K	234K
Deferred Revenue (Current)	643K	97K	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	0	7.71M	7.78M	0	30.12M	25.19M	23.16M	17.55M	0	0
Current Ratio	2.93x	3.04x	2.79x	2.06x	2.84x	2.49x	3.06x	3.99x	2.17x	3.07x
Quick Ratio	1.76x	1.72x	1.85x	1.41x	1.61x	1.63x	2.17x	2.90x	1.70x	2.19x
Cash Conversion Cycle	167.24	182.93	169.5	138.51	215.14	196.96	173.95	186.2	165.46	194.43
Total Non-Current Liabilities+	34.67M	37.87M	50.14M	42.37M	69.43M	70.31M	122.2M	118.47M	648.08M	671.41M
Long-Term Debt	30.16M	32.36M	40.84M	31.98M	38.89M	33.91M	74.38M	72.84M	589.58M	601.63M
Capital Lease Obligations	0	0	0	0	16.82M	17.74M	25.1M	23.69M	29.72M	41.88M
Deferred Tax Liabilities	497K	2.3M	2.24M	1.45M	867K	5.45M	7.07M	7.37M	6.07M	6.96M
Other Non-Current Liabilities	3.17M	3.96M	7.94M	9.36M	12.86M	13.21M	15.65M	14.56M	22.72M	20.95M
Total Liabilities	94.63M	98.48M	117.34M	149.2M	159.44M	182.51M	226.01M	213.33M	873.49M	845.17M
Total Debt+	41.1M	37.72M	47.16M	50.21M	66.63M	67.27M	104.66M	102.58M	623.64M	650.55M
Net Debt	-24.98M	-34.63M	-18.44M	-36.12M	-8.93M	-25.37M	-21.69M	-53.52M	479.35M	498.94M
Debt / Equity	0.14x	0.11x	0.14x	0.14x	0.16x	0.15x	0.23x	0.19x	0.98x	0.89x
Debt / EBITDA	6.47x	1.25x	3.16x	6.36x	3.16x	1.86x	1.09x	0.76x	2.61x	2.48x
Net Debt / EBITDA	-3.93x	-1.14x	-1.24x	-4.58x	-0.42x	-0.70x	-0.22x	-0.39x	2.01x	1.90x
Interest Coverage	-6.99x	15.32x	-1.08x	-35.49x	-0.33x	29.29x	78.97x	58.23x	7.25x	6.77x
Total Equity+	295.51M	329.25M	337.33M	364.36M	427.53M	448.72M	445.52M	528.66M	639.42M	732.3M
Equity Growth %	0.05%	0.11%	0.02%	0.08%	0.17%	0.05%	-0.01%	0.19%	0.21%	0.15%
Book Value per Share	6.57	6.93	6.97	7.85	8.57	9.13	8.95	10.08	12.06	14.07
Total Shareholders' Equity	295.51M	329.25M	337.33M	332.44M	381.37M	402.31M	445.52M	528.66M	639.42M	732.3M
Common Stock	5K	5K	5K	5K	5K	5K	6K	6K	6K	6K
Retained Earnings	60.32M	70.86M	76.23M	67.48M	116.37M	117.77M	180.34M	271.72M	409.27M	568.79M
Treasury Stock	-10.17M	-20.03M	-50.7M	-75.48M	-97.63M	-121.81M	-150.48M	-189.52M	-247.43M	-332.71M
Accumulated OCI	-2.48M	-4.7M	-2.1M	-4.01M	-4.69M	-3.72M	-6.76M	-8.62M	-8.48M	-9.18M
Minority Interest	0	0	0	31.92M	46.16M	46.42M	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	10.68M	38.56M	39.21M	38.19M	41.76M	57.27M	97.99M	89.18M	183.5M	213.39M
Operating CF Margin %	0.04%	0.15%	0.16%	0.13%	0.13%	0.16%	0.22%	0.18%	0.28%	0.29%
Operating CF Growth %	-0.49%	2.61%	0.02%	-0.03%	0.09%	0.37%	0.71%	-0.09%	1.06%	0.16%
Net Income	-2.79M	10.53M	4.51M	-6.66M	46.51M	1.1M	63.3M	91.39M	137.54M	159.52M
Depreciation & Amortization	13.25M	14.56M	15.44M	16.52M	21.12M	25.18M	26.75M	28.74M	41.78M	57.2M
Stock-Based Compensation	12.81M	15.12M	17.09M	16.68M	17.3M	20.5M	18.69M	17.86M	20.24M	24.37M
Deferred Taxes	-7.88M	-3.27M	3.93M	-1.88M	7.55M	1.12M	4.21M	-15.75M	-13.74M	-17.87M
Other Non-Cash Items	420K	1.31M	-2.34M	1.43M	1.04M	240K	-13.03M	-878K	21.89M	4.71M
Working Capital Changes	-5.14M	297K	582K	12.1M	-51.75M	9.13M	-1.92M	-32.18M	-24.21M	-14.55M
Change in Receivables	-11.01M	6.38M	-8.1M	-16.3M	6.7M	-20.16M	-14.92M	-10.13M	-26.09M	-21.67M
Change in Inventory	9.78M	-9.71M	18.65M	-5.98M	-41.1M	15.3M	1.26M	-11.75M	-1.72M	-48.8M
Change in Payables	-3.13M	-823K	6.69M	29.16M	-17.94M	14.96M	3.02M	-736K	13.24M	63.56M
Cash from Investing+	-16.93M	-39.5M	-38.76M	-42.18M	-50.53M	-36.41M	-28.67M	-32.78M	-649.12M	-124.93M
Capital Expenditures	-16.05M	-21.38M	-35.1M	-46.81M	-41.55M	-33.85M	-27.46M	-24.03M	-38.17M	-41.04M
CapEx % of Revenue	0.06%	0.08%	0.15%	0.16%	0.13%	0.1%	0.06%	0.05%	0.06%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-878K	-5.13M	-3.66M	198K	-157K	-1.41M	-2.61M	-1.37M	1.39M	-4.12M
Cash from Financing+	2.24M	7.14M	-7.72M	25.01M	-3.78M	-2.25M	-37.02M	-26.44M	454.09M	-80.95M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14.31M	21.5M	13.76M	8.95M	3.42M	23.06M	-40.24M	15.25M	-14.11M	-5.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.37M	17.18M	4.11M	-8.62M	207K	23.41M	70.54M	65.15M	145.34M	172.34M
FCF Margin %	-0.02%	0.07%	0.02%	-0.03%	0%	0.07%	0.16%	0.13%	0.23%	0.24%
FCF Growth %	-10.7%	4.2%	-0.76%	-3.1%	1.02%	112.1%	2.01%	-0.08%	1.23%	0.19%
FCF per Share	-0.12	0.36	0.08	-0.19	0.00	0.48	1.42	1.24	2.74	3.31
FCF Conversion (FCF/Net Income)	-3.83x	3.66x	8.70x	-6.66x	0.85x	40.82x	1.58x	0.98x	1.33x	1.34x
Interest Paid	1.94M	1.72M	1.88M	2.38M	2.44M	2.2M	2.11M	3.02M	17.57M	26.81M
Taxes Paid	146K	3.4M	4.88M	339K	5.72M	3.41M	8.1M	44.44M	49M	40.1M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.97%	3.37%	1.35%	-1.64%	12.36%	0.32%	13.89%	18.76%	23.55%	23.26%
Return on Invested Capital (ROIC)	-1.96%	4.16%	-0.22%	-2%	-0.01%	1.95%	12.37%	17.94%	18.54%	13.11%
Gross Margin	30.75%	40.83%	37.8%	36.31%	40.92%	40.97%	45.63%	49.87%	54.49%	51.08%
Net Margin	-1.11%	4.13%	1.88%	-1.95%	15.18%	0.4%	14.19%	18.31%	21.34%	21.79%
Debt / Equity	0.14x	0.11x	0.14x	0.14x	0.16x	0.15x	0.23x	0.19x	0.98x	0.89x
Interest Coverage	-6.99x	15.32x	-1.08x	-35.49x	-0.33x	29.29x	78.97x	58.23x	7.25x	6.77x
FCF Conversion	-3.83x	3.66x	8.70x	-6.66x	0.85x	40.82x	1.58x	0.98x	1.33x	1.34x
Revenue Growth	19.51%	1.45%	-5.87%	22.69%	9.4%	8.53%	25.13%	13.98%	29.14%	13.59%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	-	712.81M
Product Growth	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	19.15M
Other Growth	-	-	-	-	-	-	-	-	-	-
Product revenues, net	-	-	-	-	-	-	-	-	593.24M	-
Product revenues, net Growth	-	-	-	-	-	-	-	-	-	-
Other revenues	-	-	-	-	-	-	-	-	51.16M	-
Other revenues Growth	-	-	-	-	-	-	-	-	-	-
Research and development services	-	-	-	-	-	-	-	4.3M	-	-
Research and development services Growth	-	-	-	-	-	-	-	-	-	-
Finished Pharmaceutical Products	-	-	-	-	-	-	419.57M	-	-	-
Finished Pharmaceutical Products Growth	-	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	14.94M	10.04M	23.61M	20.36M	18.48M	18.2M	-	-	-
Active Pharmaceutical Ingredient Growth	-	-	-32.84%	135.22%	-13.77%	-9.23%	-1.52%	-	-	-
Epinephrine	-	-	17.8M	-	-	-	-	-	-	-
Epinephrine Growth	-	-	-	-	-	-	-	-	-	-
Recombinant Human Insulin	20.8M	-	-	-	-	-	-	-	-	-
Recombinant Human Insulin Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	419.87M	486.83M	635.19M	707.68M
UNITED STATES Growth	-	-	-	-	-	-	-	15.95%	30.47%	11.41%
FRANCE	-	-	-	-	-	-	11.88M	7.46M	4.7M	19.95M
FRANCE Growth	-	-	-	-	-	-	-	-37.23%	-37.00%	324.58%
CHINA	-	-	-	-	-	-	6.02M	4.7M	4.5M	4.34M
CHINA Growth	-	-	-	-	-	-	-	-21.98%	-4.09%	-3.68%
U	243.29M	249.01M	234.32M	279.12M	304.9M	333.09M	-	-	-	-
U Growth	-	2.35%	-5.90%	19.12%	9.23%	9.25%	-	-	-	-
C	-	-	-	-	1.48M	3.16M	-	-	-	-
C Growth	-	-	-	-	-	113.44%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Amphastar Pharmaceuticals, Inc. (AMPH) has a price-to-earnings (P/E) ratio of 8.5x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Amphastar Pharmaceuticals, Inc. (AMPH) reported $723.3M in revenue for fiscal year 2024. This represents a 254% increase from $204.3M in 2012.

Amphastar Pharmaceuticals, Inc. (AMPH) grew revenue by 13.6% over the past year. This is steady growth.

Yes, Amphastar Pharmaceuticals, Inc. (AMPH) is profitable, generating $111.6M in net income for fiscal year 2024 (21.8% net margin).

Dividend & Returns

Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity (ROE) of 23.3%. This is excellent, indicating efficient use of shareholder capital.

Amphastar Pharmaceuticals, Inc. (AMPH) generated $113.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.